📊 RLAY Key Takeaways
Is RLAY a Good Investment? Thesis Analysis
Relay Therapeutics is a pre-revenue stage biotech company with unsustainable cash burn of $235.9M annually against minimal $15.4M revenue, resulting in -$276.5M net losses. While balance sheet strength and improving loss trends show positive developments, the company faces critical cash runway of less than 5 months at current burn rates without additional capital, making near-term dilution inevitable.
Relay Therapeutics shows minimal revenue and extremely negative profitability, with operating and free-cash-flow losses that materially exceed current cash and equivalents. While the company has a debt-free balance sheet, high current ratio, and modest YoY loss improvement, the cash burn implies a need for additional financing absent sizable partnership inflows or clinical catalysts translating to revenue. On fundamentals alone, near-term risk outweighs growth quality.
Why Buy RLAY? Key Strengths
- Strong balance sheet with $567.1M stockholders equity and minimal debt (0.00x Debt/Equity)
- Excellent liquidity position (22.61x current ratio) with $84M in cash equivalents
- Net losses improving significantly year-over-year (-18.1% loss improvement suggests operational progress)
- Debt-free balance sheet with low liabilities
- Very high current ratio and sizable equity base
- Net loss and EPS improving YoY with minimal capex needs
RLAY Investment Risks to Consider
- Catastrophic cash burn of $235.9M annually with less than 5-month runway; company cannot operate without significant capital raises
- Flat revenue growth at $15.4M with zero YoY expansion despite public company status, indicating no commercialization progress
- Operating losses of -$302.7M and negative operating cash flow of -$235.5M demonstrate unsustainable business model with no path to near-term profitability
- Heavy operating and FCF burn relative to cash on hand, raising dilution/financing risk
- Revenue is small, flat YoY, and reliant on uncertain milestone/partner payments
- Clinical and regulatory execution risk could delay commercialization and extend losses
Key Metrics to Watch
- Monthly cash burn rate and cash runway projection
- Revenue growth acceleration and potential product approvals/launches
- Operating expense control and R&D spending efficiency
- Quarterly operating cash flow (burn rate)
- Total liquidity (cash + short‑term investments) and cash runway
RLAY Financial Metrics
💡 AI Analyst Insight
Strong liquidity with a 22.61x current ratio provides a solid financial cushion.
RLAY Profitability Ratios
RLAY vs Healthcare Sector
How Relay Therapeutics, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is RLAY Overvalued or Undervalued?
Based on fundamental analysis, Relay Therapeutics, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
RLAY Balance Sheet & Liquidity
RLAY 5-Year Financial Trend & Growth Analysis
5-Year Trend Summary: Relay Therapeutics, Inc.'s revenue has declined by 69% over the 5-year period, indicating business contraction. The most recent EPS of $-2.79 indicates the company is currently unprofitable.
RLAY Growth Metrics (YoY)
RLAY Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | N/A | -$70.4M | $-0.43 |
| Q2 2025 | N/A | -$70.4M | $-0.41 |
| Q1 2025 | $7.7M | -$77.1M | $-0.46 |
| Q3 2024 | $10.0M | -$65.7M | $-0.54 |
| Q2 2024 | $119.0K | -$81.4M | $-0.69 |
| Q1 2024 | $226.0K | -$81.4M | $-0.62 |
| Q3 2023 | $344.0K | -$62.0M | $-0.54 |
| Q2 2023 | $119.0K | -$62.0M | $-0.71 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
RLAY Capital Allocation
RLAY SEC 10-K & 10-Q Filing Analysis
Access official SEC EDGAR filings for Relay Therapeutics, Inc. (CIK: 0001812364)
📋 Recent SEC Filings
❓ Frequently Asked Questions about RLAY
What is the AI rating for RLAY?
Relay Therapeutics, Inc. (RLAY) has a Combined AI Rating of SELL from Claude (SELL) and ChatGPT (SELL) with 78% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are RLAY's key strengths?
Claude: Strong balance sheet with $567.1M stockholders equity and minimal debt (0.00x Debt/Equity). Excellent liquidity position (22.61x current ratio) with $84M in cash equivalents. ChatGPT: Debt-free balance sheet with low liabilities. Very high current ratio and sizable equity base.
What are the risks of investing in RLAY?
Claude: Catastrophic cash burn of $235.9M annually with less than 5-month runway; company cannot operate without significant capital raises. Flat revenue growth at $15.4M with zero YoY expansion despite public company status, indicating no commercialization progress. ChatGPT: Heavy operating and FCF burn relative to cash on hand, raising dilution/financing risk. Revenue is small, flat YoY, and reliant on uncertain milestone/partner payments.
What is RLAY's revenue and growth?
Relay Therapeutics, Inc. reported revenue of $15.4M.
Does RLAY pay dividends?
Relay Therapeutics, Inc. does not currently pay dividends.
Where can I find RLAY SEC filings?
Official SEC filings for Relay Therapeutics, Inc. (CIK: 0001812364) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is RLAY's EPS?
Relay Therapeutics, Inc. has a diluted EPS of $-1.61.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is RLAY a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Relay Therapeutics, Inc. has a SELL rating with 78% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is RLAY stock overvalued or undervalued?
Valuation metrics for RLAY: ROE of -48.8% (sector avg: 15%), net margin of -1,800.6% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy RLAY stock in 2026?
Our dual AI analysis gives Relay Therapeutics, Inc. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is RLAY's free cash flow?
Relay Therapeutics, Inc.'s operating cash flow is $-235.5M, with capital expenditures of $410.0K. FCF margin is -1,536.1%.
How does RLAY compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -1,800.6% (avg: 12%), ROE -48.8% (avg: 15%), current ratio 22.61 (avg: 2).